Buy CJC-1295 W/ DAC 2mg

£27.99

  • HPLC Purity: ≥98%
  • Quantity: 2mg
  • Compound: CJC-1295 with Drug Affinity Complex (DAC)
  • Research class: Long-acting synthetic GHRH analogue
  • Storage: Lyophilised; store at −20°C for long-term laboratory storage
  • Format: Lyophilised powder
  • Research focus: GHRH receptor signalling, growth-hormone pathway research, and sustained IGF-1 signalling in preclinical research models.

CJC-1295 with DAC is a modified GHRH analogue incorporating a Drug Affinity Complex designed to extend peptide exposure through albumin binding. It is studied in in-vitro testing, preclinical research, adipose cell culture studies, and qualified laboratory experimentation investigating prolonged GHRH/GH/IGF-1 pathway signalling.

Buy More, Save More!

Buy More, Save More!
Quantity Discount Price You save
3, 4 3% off £27.15 £0.84
5, 9 5% off £26.59 £1.40
10, 14 10% off £25.19 £2.80
15, 24 15% off £23.79 £4.20
25+ Best value 20% off £22.39 £5.60
Category:
Description

Buy CJC-1295 W/ DAC 2mg – Loti Labs UK

Compound Overview & Technical Specifications

CJC-1295 with Drug Affinity Complex (DAC) is a long-acting synthetic analogue of growth hormone-releasing hormone (GHRH) investigated in laboratory and preclinical research for its extended exposure profile. The molecule incorporates modifications associated with Mod GRF 1-29 together with a Drug Affinity Complex designed to promote albumin association.

The DAC modification is a distinguishing feature of this research compound. Its maleimide-containing functionality has been investigated for covalent association with circulating albumin, providing a research model for examining prolonged GHRH pathway stimulation compared with shorter-acting GHRH analogues.

Technical Specifications

  • Product: CJC-1295 W/ DAC
  • Quantity: 2mg
  • HPLC Purity: ≥98%
  • Compound Type: Modified GHRH analogue
  • Drug Affinity Complex: Maleimidoproprionic acid (MPA) modification
  • Research Pathway: GHRH receptor / Gs / adenylyl cyclase / cAMP / PKA signalling
  • Primary Research Areas: GH secretion, IGF-1 signalling, peptide pharmacokinetics and endocrine pathway research
  • Physical Form: Lyophilised powder
  • Intended Application: Laboratory research use only

Sequence & Molecular Information

CJC-1295 DAC incorporates the four amino-acid substitutions associated with Mod GRF 1-29, together with a C-terminal Drug Affinity Complex. The DAC modification is designed to alter the peptide’s pharmacokinetic characteristics through albumin association.

The supplied product should be evaluated against the manufacturer’s analytical documentation for batch-specific molecular and purity information before qualified laboratory experimentation.

Storage & Laboratory Handling

  • Store the lyophilised peptide at −20°C for long-term laboratory storage.
  • Protect from moisture, excessive heat and unnecessary temperature fluctuations.
  • Reconstitution should be conducted by appropriately qualified laboratory personnel using an appropriate research-grade solvent and suitable laboratory procedures.
  • Reconstituted material should be handled according to validated laboratory storage and stability protocols.
  • Avoid prolonged exposure to unsuitable pH or elevated temperatures.
  • HPLC analysis may be used to confirm analytical purity before experimental work.

Mechanism of Action & Research Context

GHRH Receptor Signalling

CJC-1295 DAC is investigated as a GHRH analogue capable of interacting with GHRH receptors associated with pituitary somatotroph signalling.

Activation of the GHRH receptor is associated with the Gs protein, adenylyl cyclase, cyclic AMP and protein kinase A signalling pathway. This provides an experimental framework for investigating the regulation of growth-hormone-related signalling under controlled laboratory conditions.

Drug Affinity Complex & Albumin Association

The principal research characteristic of CJC-1295 DAC is its Drug Affinity Complex. The maleimide-containing modification has been studied for its ability to form a stable covalent association with albumin.

Albumin association can substantially alter peptide exposure compared with shorter-acting GHRH analogues. This makes CJC-1295 DAC relevant to experimental studies examining sustained versus transient stimulation of the GHRH/GH/IGF-1 signalling axis.

Sustained GH & IGF-1 Research

Preclinical and pharmacokinetic research has examined CJC-1295 DAC in relation to prolonged stimulation of growth-hormone secretion and sustained IGF-1 signalling.

This extended exposure profile provides researchers with an experimental model for investigating the biological consequences of longer-duration pathway activation rather than relying exclusively on short-lived signalling events.

Comparative Research With Shorter-Acting GHRH Analogues

CJC-1295 DAC can be compared experimentally with shorter-acting GHRH analogues to investigate how different exposure profiles affect research endpoints.

CJC-1295 without DAC is generally studied as a shorter-acting analogue, while the DAC modification provides a model for prolonged peptide exposure. This distinction can be useful in controlled research investigating temporal differences in GHRH/GH/IGF-1 pathway activity.

Preclinical Research Applications

CJC-1295 W/ DAC may be investigated in qualified laboratory research involving:

  • GHRH receptor signalling
  • Somatotroph pathway research
  • GH and IGF-1 signalling
  • Peptide pharmacokinetics
  • Albumin-binding research
  • Sustained versus transient endocrine signalling
  • In-vitro cellular pathway studies
  • Adipose cell culture research
  • Preclinical investigation of GHRH analogues

Literature & Citation Index

Key Scientific References

  • Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799–805.
  • Jetté L, et al. hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: comparison with hGRF1-44 NH2. 2005;146(7):3052–3058.
  • Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews. 2018;6(1):45–53.
  • Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews. 1998;19(6):717–797.

Laboratory Terms & Compliance

Laboratory Research Use Only.

CJC-1295 W/ DAC 2mg is supplied exclusively as a research compound for qualified laboratory experimentation. It is intended for in-vitro testing, preclinical research, adipose cell culture studies and controlled laboratory research applications only.

This product is not intended for human consumption, clinical use, veterinary use, diagnosis, treatment or prevention of disease, or administration to humans or animals.

All laboratory handling, storage, testing and disposal should be conducted by appropriately qualified personnel in accordance with applicable laboratory procedures and relevant UK/EU requirements.

Additional information
Purity

≥99%

Form

Lyophilised vial

Research Purpose

For laboratory research purposes only.

Drug Affinity Complex

With DAC

Quantity

2mg

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Buy CJC-1295 W/ DAC 2mg”